ClinicalTrials.gg
RecruitingNCT06091475TRED-HF2Updated Sep 19, 2024

Therapy to Maintain Remission in Dilated Cardiomyopathy

An interventional study of Other in Heart Failure, Cardiomyopathy, Dilated and Cardiomyopathies, sponsored by Imperial College London. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Imperial College London · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Heart Failure by Imperial College London — 7 open to participants now, 8 under way, none of them phase 3. Heart Failure · Imperial College London.

Planned enrollment
10th of 18
50 · median 55
Started
2023
with 4 others
No phase
11 of 29
5 open now
Registered
25th of 29
by date

Among the 29 studies in Heart Failure by Imperial College London, this one is the 10th largest by planned enrollment of the 18 interventional ones that give a count, is one of 5 that started in 2023, is one of 11 with no phase, and was the 25th registered.

Heart Failure

6,339 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

7 of the 29 studies in Heart Failure by Imperial College London are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Heart Failure by Imperial College London, or all of them as a file.
02

Study summary

One third of patients diagnosed with heart failure demonstrate left ventricular reverse remodelling and recovery of cardiac function following a period of medical therapy. The TRED-HF trial investigated the impact of therapy withdrawal in this cohort and found that 40% of patients relapsed within 6 months of stopping treatment. In this follow-on study, the investigators will investigate the safety of therapy withdrawal of sodium cotransporter 2 inhibitors (SGLT2i) and mineralocorticord receptor anatagonists (MRAs) in patients with a previous diagnosis of heart failure and recovered cardiac function, in a randomised controlled trial to assess whether this maintains remission in this population.

Read the detailed description

One third of patients diagnosed with heart failure demonstrate left ventricular reverse remodelling and recovery of cardiac function following a period of medical therapy. These patients have an excellent long-term prognosis. Whether they need to remain on long-term medical therapy is not clear. Current guideline directed treatment of patients with heart failure relies on a combination of (1) angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs), (2) beta-blockers, (3) mineralocorticoid antagonists, and (4) sodium-glucose co-transporter 2 inhibitors (SGLT2i).

The TRED-HF trial, confirmed that complete withdrawal of beta-blockers, ACEi or ARBs, and MRAs resulted in relapse within 6 months in 40% of asymptomatic patients with a previous diagnosis of DCM and improved cardiac function. This confirmed that many patients have heart failure remission rather than sustained recovery and still benefit from at least some pharmacological therapy. Defining the therapies required to maintain heart failure remission is a priority for heart failure research, taking into account the changing therapeutic needs of many millions of patients following improvement in their cardiac function. In this follow-on study to the TRED-HF trial, the investigators will carry out an open-label, randomised clinical trial examining the safety and feasibility of sequential mineralocorticoid receptor antagonist (MRA) and sodium glucose co-transporter 2 inhibitor (SGLT2i) withdrawal in 50 patients with dilated cardiomyopathy who are now in heart failure remission and taking angiotensin system inhibitors and beta-blockers. Patients will have serial cardiovascular magnetic resonance (CMR) scans and circulating biomarkers after withdrawal of each therapy and will be followed for 8 months. The primary end-point will be relapse of heart failure defined by features of adverse remodelling.

03

Conditions studied

  • Heart Failure
  • Cardiomyopathy, Dilated
  • Cardiomyopathies
  • Heart Diseases

Keywords

  • Cardiomyopathy
  • heart failure
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. a diagnosis of dilated cardiomyopathy,
  2. previous (LVEF) \<40% (on echocardiography or cardiovascular magnetic resonance [CMR]),
  3. current LVEF >50% with normal left ventricular end-diastolic volume (LVEDV),
  4. plasma NT-pro-BNP\<250ng/L,
  5. (NYHA) class I,
  6. sinus rhythm,
  7. taking a beta-blocker and an angiotensin converting enzyme inhibitor (ACEi), angiotensin receptor blocker (ARB) or sacubitril-valsartan, along with either a mineralocorticoid receptor antagonist (MRA) and/or sodium glucose co-transporter 2 inhibitor (SGLT2i).

Exclusion criteria

Exclusion Criteria:

  1. Atrial fibrillation,
  2. prior sustained ventricular tachycardia or fibrillation,
  3. a known likely pathogenic or pathogenic variant in LMNA/DSP/FLNC/RBM20,
  4. sudden cardiac or heart failure death in a first degree relative \<50 years,
  5. to CMR,
  6. estimated (eGFR) \<60mls/min,
  7. planned pregnancy,8) active myocardial inflammation,
  1. diabetes mellitus managed with an SGLT2i, 10) urinary albumin-to-creatine ratio of 200-5000 (mg:g) and eGFR\< 75mls/min.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Withdrawal of treatment with eplerenone or spironolactone, and empagliflozin and dapalgiflozin

    Gradual, supervised withdrawal of ineralocorticoid receptor antagonists (spironolactone or eplerenone) and sodium glucose cotransporter 2 inhibitor (dapagliflozin or empagliflozin) over 4-16 weeks. Continued monitoring off study therapies during the cross-over phase.

    Drug: Other

  • No intervention
    Continued treatment with eplerenone or spironolactone, and empagliflozin and dapagliflozin

    Continuation of usually prescribed pharmacological therapy over 16 weeks followed by cross-over to withdrawal of SGLT2i and MRA over the subsequent 4-16 weeks.

Interventions

  • DrugOther

    Withdrawal of mineralocorticoid receptor antagonists and/or sodium glucose cotransporter 2 inhibitors

    Also known as: Withdrawal of spironolactone or eplerenone and dapagliflozin or empagliflozin

06

What researchers measure

Primary outcomes

  1. Heart Failure Relapse assessed through left ventricular ejection fraction (LVEF)

    Relapse of DCM defined by a reduction in LVEF\>10% and to below 50%

    Time frame: 32 weeks

  2. Heart Failure Relapse assessed through pro-BNP

    Relapse of DCM defined by a two-fold rise in NT-pro-BNP and to \>400ng/L

    Time frame: 32 weeks

  3. Number of patients with heart failure Relapse assessed through signs of heart failure

    Relapse of DCM defined by clinical signs of heart failure as determined by the research team

    Time frame: 32 weeks

  4. Number of patients with heart failure Relapse assessed through symptoms of heart failure

    Relapse of DCM defined by clinical symptoms of heart failure as determined by the research team

    Time frame: 32 weeks

Secondary outcomes

  1. Left ventricular ejection fraction (LVEF)

    Change in LVEF between baseline, during randomised phase (0-16 weeks) and follow-on phase (16-32 weeks)

    Time frame: 32 weeks

  2. Left Ventricular End-Diastolic Volume Index indexed to body surface area (ml/m2) (LVEDVi)

    Change in LVEDVi between baseline, during randomised phase (0-16 weeks) and follow-on phase (16-32 weeks)

    Time frame: 32 weeks

  3. left ventricular global longitudinal strain (LV GLS)

    Change in LV GLS between baseline, during randomised phase (0-16 weeks) and follow-on phase (16-32 weeks)

    Time frame: 32 weeks

  4. left ventricular mass index (LVMi; g/m2)

    Change in LVMI between baseline, during randomised phase (0-16 weeks) and follow-on phase (16-32 weeks)

    Time frame: 32 weeks

  5. left atrial volume index (LAVi; ml/m2)

    Change in LAVi between baseline, during randomised phase (0-16 weeks) and follow-on phase (16-32 weeks)

    Time frame: 32 weeks

  6. left atrial strain (LAS)

    Change in LAS between baseline, during randomised phase (0-16 weeks) and follow-on phase (16-32 weeks)

    Time frame: 32 weeks

  7. right ventricular ejection fraction (RVEF; %)

    Change in RVEF between baseline, during randomised phase (0-16 weeks) and follow-on phase (16-32 weeks)

    Time frame: 32 weeks

  8. Change in Quality of Life (EQ-5D-5L score)

    Assessed through EQ-5D-5L score. This is a validated score from the EuroQoL research foundation, graded from 5 to 25 with a higher score reflecting a worse quality of life

    Time frame: 32 weeks

  9. Change in Quality of Life (Treatment Burden Questionnaire score)

    Assessed through TBQ (Treatment Burden Questionnaire) score. The TBQ score is graded from 0 to 150 with a higher score reflecting a greater treatment burden

    Time frame: 32 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Halliday BP, Wassall R, Lota AS, Khalique Z, Gregson J, Newsome S, Jackson R, Rahneva T, Wage R, Smith G, Venneri L, Tayal U, Auger D, Midwinter W, Whiffin N, Rajani R, Dungu JN, Pantazis A, Cook SA, Ware JS, Baksi AJ, Pennell DJ, Rosen SD, Cowie MR, Cleland JGF, Prasad SK. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet. 2019 Jan 5;393(10166):61-73. doi: 10.1016/S0140-6736(18)32484-X. Epub 2018 Nov 11. PubMed 30429050 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Aug 2026, 32 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 32 months is above that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2023
First posted
Oct 19, 2023
StartActual
Dec 2, 2023
Primary completionEst.
Aug 15, 2026
CompletionEst.
Sep 15, 2026
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06091475
Responsible party
Sponsor
First posted
Oct 19, 2023
Start date
Dec 2, 2023
Primary completion
Aug 15, 2026 (estimated)
Completion
Sep 15, 2026 (estimated)
Last update
Sep 19, 2024

Study contacts

Saad Javed, MBChB
Contact
tred2trial@imperial.ac.uk
02073528121
Brian P Halliday, MBChB
principal investigator · Imperial College London, Royal Brompton Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion